Delving into the Latest Updates on Cisplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CACP, CDDP, CIS-DDP

+ [27]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [9]

Active Indication

Biliary Tract NeoplasmsSquamous Cell Carcinoma of Head and NeckMalignant Pleural Mesothelioma+ [72]

Inactive Indication

Adenocarcinoma of EsophagusAdvanced Bile Duct CarcinomaAdvanced Cervical Carcinoma+ [97]

Originator Organization

HQ Specialty Pharma Corp.

Privo Technologies, Inc.

Active Organization

Eli Lilly & Co.

AstraZeneca PLC

Sanofi

+ [27]

Inactive Organization

Bayer AG

Pfizer Inc.EMD Serono Research & Development Institute, Inc.

+ [15]

License Organization

Chosa Oncology AB

Eleison Pharmaceuticals, Inc.

Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (19 Dec 1978),

Bladder CancerOvarian CancerTesticular Neoplasms

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.

Start Date24 Nov 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Cisplatin

Login to view more data

100 Translational Medicine associated with Cisplatin

Login to view more data

100 Patents (Medical) associated with Cisplatin

Login to view more data

103,809

Literatures (Medical) associated with Cisplatin

31 Dec 2026·CANCER BIOLOGY & THERAPY

Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN

Article

Author: Zhao, Wen ; Su, Yan ; Gao, Chao ; Cui, Chunying ; Duan, Chao ; Li, Lan ; Xue, Tianlin ; He, Sidou ; Liu, Shuguang ; Yue, Zhixia

BACKGROUND:

Current risk stratification for neuroblastoma (NB) relies on limited markers like MYCN amplification. Coilin, a key Cajal body component, regulates cellular processes. This study investigates whether coilin expression in bone marrow (BM) serves as a predictive biomarker for NB progression and elucidate its function in this disease.

METHODS:

The functions and molecular mechanisms of coilin were investigated by employing cell lines and animal models. Coilin mRNA levels in patient samples were measured by RT-PCR, and their relationships with clinicobiological characteristics and outcomes were analyzed.

RESULTS:

Cisplatin induced dramatic changes of coilin distribution and expression. Databases showed that high expression of coilin exerted predictive values for poor outcome in NB. Coilin promoted proliferation in vitro and in vivo. Knockdown of coilin expression inhibited cell migration and invasion, promoted apoptosis and increased the Cisplatin drug sensitivity. Moreover, coilin activates p53/p21 signaling pathway and was a direct target of MYCN. Analysis of BM samples demonstrated that high expression of coilin was obviously associated with adverse clinical biological features. Importantly, the levels of coilin at diagnosis were markedly higher than those at the time before maintenance treatment in the exact paired patients. Survival analysis presented that high coilin expression in BM is associated with poor prognosis.

CONCLUSIONS:

A novel and accessible coilin-targeted liquid biopsy method was developed, capable of detecting minimal residual disease (MRD) in early-stage NB and predicting disease progression and recurrence. Coilin was transcriptionally regulated by MYCN, offering potential avenues for the development of novel drugs or intervention strategies.

31 Dec 2026·RENAL FAILURE

Bergamottin pretreatment attenuates cisplatin-induced acute kidney injury in mice by inhibiting BACE-1-mediated ferroptosis

Article

Author: Yuan, Hui-feng ; Wang, Ya-jie ; Peng, Song ; Yang, Xue-ping ; Xu, You-song

Bergamottin is a natural furanocoumarin compound that possesses antioxidative and anticancer properties. However, the effect of bergamottin (BGM) on acute kidney injury (AKI) is unknown. Human renal tubular HK-2 cells and mice that received cisplatin were pretreated with BGM, after which their cytotoxicity and renal function were evaluated. BGM pretreatment alleviated cisplatin-induced cytotoxicity in vitro. Moreover, synergistic protection against cisplatin-induced cytotoxicity was observed when BGM and apoptosis, autophagy, or necrosis inhibitors were used together. There was no synergistic effect between BGM and the ferroptosis inhibitor. Furthermore, BGM significantly inhibited ferroptosis induction-induced damage to HK-2 cells. BGM pretreatment alleviated renal dysfunction and pathological damage by reducing renal proinflammatory cytokines and inhibiting inflammatory cell infiltration, lipid peroxidation and ferroptosis. Based on predictions by SwissTarget and molecular docking, BGM strongly interacts with residues of beta-secretase 1 (BACE-1) via hydrogen and hydrophobic interactions. Moreover, BACE-1 expression was significantly upregulated in the kidneys of AKI mice and HK-2 cells treated with cisplatin but markedly reduced following BGM intervention. Interestingly, siRNA-mediated silencing of BACE-1 in vitro substantially abolished the protective effect of BGM on HK-2 cells that received cisplatin. BGM effectively alleviated AKI by targeting BACE-1 to reduce ferroptosis, suggesting that BGM could be developed as a potential agent for managing and pretreating AKI.

31 Dec 2026·ANNALS OF MEDICINE

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma

Review

Author: Liu, Jiajun ; Qian, Fenhong

BACKGROUND:

Non-small cell lung carcinoma (NSCLC) remains a leading cause of cancer-related mortality worldwide, with existing therapies frequently hindered by drug resistance and immunosuppression. Metabolic reprogramming (glycolysis, lipid metabolism, and amino acid metabolism) has emerged as a core hallmark driving NSCLC progression, tumor microenvironment (TME) remodeling, and treatment failure, transcending the classical Warburg effect to involve intricate cross-talk between cancer cells and stromal components.

DISCUSSION:

This review systematically synthesizes the latest insights into the regulatory mechanisms of metabolic reprogramming in NSCLC, highlighting how dysregulated glycolytic flux, altered lipid synthesis/oxidation, and adaptive amino acid utilization collectively sustain tumor growth, invasion, and immune escape. We critically examine the interplay between metabolic reprogramming and driver gene mutations (EGFR/KRAS/ALK), unraveling how mutation-specific metabolic adaptations contribute to targeted therapy resistance, and explore the role of metabolic heterogeneity in shaping treatment responses. Furthermore, we dissect actionable therapeutic strategies that target metabolic vulnerabilities, including immunotherapy synergies (e.g. PD-1 inhibitors combined with PKM2/ferroptosis targeting, metabolically modified CAR-T cells), subtype-specific targeted interventions (e.g. DPP4/GFPT2/PFKFB3 inhibitors reversing mutation-driven metabolic resistance), and chemotherapy sensitization approaches (e.g. CPT1A/GLUD1 inhibitors overcoming cisplatin resistance via suppressing metabolic compensation).

CONCLUSION:

This review underscores the clinical potential of targeting metabolic reprogramming to address unmet therapeutic needs, proposing synergistic regimens and personalized metabolic therapy frameworks that hold promise for improving NSCLC patient outcomes.

1,475

News (Medical) associated with Cisplatin

28 May 2026

·firstwordpharma.com

Imfinzi regimen cleared in US for BCG-naïve, high-risk bladder cancer

AstraZeneca's Imfinzi (durvalumab) added another indication to its label on Thursday, broadening the PD-L1 inhibitor's reach in bladder cancer. The FDA approved the checkpoint inhibitor in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy to treat adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC)."The durvalumab plus BCG regimen is the first new therapy approved in over 30 years for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer," said Neal Shore, co-principal investigator of the Phase III POTOMAC trial, data from which supported the combination's clearance. Calling it a first for an immunotherapy combination regimen in the specific NMIBC patient population, Dave Fredrickson, EVP of AstraZeneca's oncology haematology business unit, said the approval "builds on the positive impact Imfinzi is already having in muscle-invasive disease," with Imfinzi plus BCG representing "an important advance for patients at risk of early disease recurrence [that] signals a shift in the standard of care."Imfinzi was approved by the FDA last year to treat cisplatin-eligible MIBC, based on findings from the Phase III NIAGARA trial, which showed the PD-L1 inhibitor reduced the risk of death by 25%.Next in bladder cancer, AstraZeneca is targeting patients with MIBC undergoing radical cystectomy who are not eligible for or have declined cisplatin. The UK pharma earlier this month shared data from the Phase III VOLGA trial in that specific population, showing that perioperative Imfinzi plus neoadjuvant treatment with Astellas and Pfizer's Padcev (enfortumab vedotin) demonstrated statistically significant improvements in event-free survival and overall survival.Risk reduction resultsPOTOMAC randomised 1018 patients who had undergone transurethral resection of bladder tumour (TURBT) to receive Imfinzi plus BCG induction and maintenance therapy, or Imfinzi plus BCG induction-only therapy, versus BCG induction and maintenance therapy.After one year, the trial met its primary endpoint with the Imfinzi-plus-BCG arm involving induction and maintenance therapy leading to a statistically significant and clinically meaningful improvement in disease-free survival (DFS) compared to BCG induction and maintenance therapy alone.Specifically, the regimen demonstrated a 32% reduction in the risk of high-risk disease recurrence, progression or death in the NMIBC patient population compared with BCG alone. AstraZeneca said global applications for Imfinzi based on the POTOMAC data are under review in the EU, Japan and several other countries.

Clinical ResultPhase 3Drug ApprovalImmunotherapy

27 May 2026

·ir.chosaoncology.com

Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB

May 27, 2026 · Regulatory information The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on 27 May 2026, the annual general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below. Resolution on adoption of accounts and distribution of the company’s profit The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also resolved to distribute the company’s profit in accordance with the proposal from the board meaning that no dividends are paid and that available funds are carried forward. Discharge from liability for the members of the board and the CEO The annual general meeting resolved to discharge the members of the board and the CEO from liability for the financial year 2025. Election of board members and auditor as well as remuneration for the board members and auditor The annual general meeting resolved in accordance with the proposal from Buhl Krone Holding ApS (the ”Proposer”) to re-elect Ingrid Atteryd Heiman, Claus Frisenberg Pedersen, Ulla Hald Buhl, Morten Myrhøj and Fred R. Hirsch as ordinary board members. Ingrid Atteryd Heiman was re-elected as Chairman of the board. Neil Goldsmith had declined re-election. Remuneration to the board shall be paid with SEK 150,000 to the Chairman of the board and with SEK 75,000 to each of the other board members. Board remuneration shall not be paid to Claus Frisenberg Pedersen and Ulla Hald Buhl. Furthermore, the annual general meeting resolved, in accordance with the proposal from the Proposer, to re-elect Deloitte AB as auditor and that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Deloitte AB has informed that Maria Ekelund will continue to be appointed as the responsible auditor. Resolution on authorization regarding issues The annual general meeting resolved, in accordance with the proposal from the board of directors, to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders’ preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares, convertibles and/or warrants. The reason why a deviation from the shareholders’ preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent that the authorization is used for an issue with deviation from the shareholders’ preferential rights, the issue shall take place on market terms. Lund on 27 May 2026 Chosa Oncology AB (publ) For additional information, contact: Peter Buhl Jensen, CEO Peter@chosa.bio + 45 21 60 89 22 This information was submitted for publication, through the agency of the contact person set out above, on 27 May 2026. CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care. About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. Immunotherapy Cisplatin and carboplatin have often been shown to activate the immune system, potentially making “cold” tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer, bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA’s approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners. 1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026 DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.

Clinical ResultPhase 2ImmunotherapyExecutive ChangeLicense out/in

26 May 2026

·www.prnewswire.com

Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session

HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in Chicago, Illinois. Notably, the presentations include one Late-Breaking Abstract (LBA) selected for the prestigious Plenary Session, alongside four Oral or Rapid Oral presentations. The datasets featured at ASCO 2026 primarily highlight the Company's core first-in-class bispecific antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations include several potentially practice-changing datasets across multiple tumor types. A pivotal highlight will be the Phase III overall survival (OS) results from the HARMONi-6 study, evaluating the survival advantage of ivonescimab combined with chemotherapy versus a PD-1 inhibitor combined with chemotherapy in the first-line setting for advanced squamous non-small cell lung cancer (sq-NSCLC). Additional notable presentations feature ivonescimab in small-cell lung cancer (SCLC) that has progressed after first-line chemoimmunotherapy, ivonescimab plus chemotherapy in first-line metastatic colorectal cancer (mCRC) from a global Phase II interim analysis, alongside cadonilimab-based regimens in renal cell carcinoma, melanoma, colorectal cancer, head and neck cancer, gynecologic malignancies, and biliary tract cancer. The maturity and breadth of these datasets underscore the success of Akeso's innovation engine, demonstrating the clinical benefits of the Company's differentiated bispecific antibody platform to the international oncology community. Key Presentations Plenary Session Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 study Abstract: LBA4 Session: Plenary Session Date/Time (CDT): May 31, 2026, 2:47 PM–2:59 PM Presenter: Professor Shun Lu, Shanghai Chest Hospital Oral Presentation Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, Phase 2 study Abstract: 8007 Date: June 2, 2026 Presenter: Professor Yun Fan, Zhejiang Cancer Hospital Oral Presentation A prospective, multicenter, Phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma Abstract: 4501 Date: June 2, 2026 Presenter: Dr. Junru Chen, West China Hospital, Sichuan University Rapid Oral Presentation Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory Phase II study Abstract: 6014 Date: June 2, 2026 Presenter: Professor Kunyu Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Rapid Oral Presentation Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a Phase Ib trial Abstract: 9516 Date: May 31, 2026 Presenter: Professor Lili Mao, Peking University Cancer Hospital International Multicenter Phase II Study Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase II study Abstract: 3576 Date: May 30, 2026 First Author: David Berz, MD, PhD, Department of Oncology, Valkyrie Clinical Trials, Inc About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. Forward-Looking Statements This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. SOURCE Akeso, Inc. 21% more press release views with Request a Demo

ASCOPhase 2Phase 3Clinical ResultImmunotherapy

100 Deals associated with Cisplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00275	Cisplatin	L01XA01	DB00515

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Biliary Tract Neoplasms	Japan	Nippon Kayaku Co., Ltd.	22 Feb 2012
Squamous Cell Carcinoma of Head and Neck	Brazil	Libbs Farmacêutica Ltda.	22 Jan 2007
Malignant Pleural Mesothelioma	Japan	Nippon Kayaku Co., Ltd.	04 Jan 2007
Childhood Malignant Solid Neoplasm	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Bone Cancer	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Endometrial Carcinoma	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Germinoma	Japan	Nippon Kayaku Co., Ltd.	31 May 2004
Hepatocellular Carcinoma	Japan	Nippon Kayaku Co., Ltd.	29 Jan 2004
Osteosarcoma	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Small Cell Lung Cancer	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Solid tumor	China	Yunnan Phytopharmaceutical Co. Ltd.	01 Jan 1995
Solid tumor	China	Qilu Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Kunming Guiyan Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Dezhou Bocheng Pharmaceutical Technology Co., Ltd.	01 Jan 1995
Solid tumor	China	Dezhou Deyao Intelligent Pharmacy Co., Ltd.	01 Jan 1995
Stomach Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Jun 1990
Esophageal Carcinoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Neuroblastoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	30 May 1988

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscle Invasive Bladder Carcinoma	Phase 3	Australia	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Brazil	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Canada	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	France	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Italy	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Netherlands	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Spain	AstraZeneca PLC	15 May 2025
Squamous cell carcinoma of the oral cavity	Phase 3	United States	Privo Technologies, Inc.	07 Nov 2024
Fallopian Tube Carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Primary peritoneal carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05712356 (BOLSTER, CTgov)	Phase 2	Intrahepatic Cholangiocarcinoma \| Advanced Malignant Solid Neoplasm \| Gallbladder Carcinoma	66	gemcitabine+Cisplatin+Durvalumab+certepetide (LSTA1 Arm for Untreated Cholangiocarcinoma)	dyefaxjczi = eyhiltabaz rxhwqujhqr (mygntzcmvx, srjsxsisyo - dtrhuryeuk) View more	-	26 May 2026
				FOLFOX regimen+certepetide (LSTA1 Arm for Second-Line Cholangiocarcinoma)	dyefaxjczi = podjmlpbzo rxhwqujhqr (mygntzcmvx, vfcljkskas - ehfoamrqgo) View more
NCT03915444 (CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Pancreatic Ductal Adenocarcinoma \| Metastatic Pancreatic Ductal Adenocarcinoma	42	NS+nab-Paclitaxel+gemcitabine+Cisplatin	gzxznfwhvf = hygieowqla ogpfwbvmqb (hhtdmbzbgv, yzipmnwirh - hlmnyxtbne) View more	-	23 Apr 2026
NCT04308174 (DEBATE, AACR2026)	Phase 2	Biliary Tract Neoplasms Neoadjuvant	45	Durvalumab plus Gemcitabine-Cisplatin (D+GP)	qzhsqbvkkk(hvyvvlwfon) = klhjwxggbj gvfendsksl (gzssbvinjq ) View more	Positive	21 Apr 2026
				Gemcitabine-Cisplatin (GP)	qzhsqbvkkk(hvyvvlwfon) = xcfownlcto gvfendsksl (gzssbvinjq ) View more
NCT04457284 (AACR2026)	Phase 2	Metastatic Colorectal Carcinoma MSH2 \| MSI \| TMB	16	TMZ+CDDP+nivolumab	abhscrqzhs(ramagvtrvg) = uazjgbyejx ptedbapven (sjozrgpvpm )	Positive	19 Apr 2026
NCT05498220 (CTgov)	Phase 2	Diffuse large B-cell lymphoma recurrent	5	Hyaluronidase+Polatuzumab vedotin+GCSF+Gemcitabine+cisplatin+Dexamethasone+Rituximab+PV	dpvurtgbqa = ggadoxkjov olbnlnlnau (gyfkorcqev, oempvlhhbk - zgnkuolozp) View more	-	16 Apr 2026
NCT00076310 (CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic \| Recurrent Squamous Cell Carcinoma of the Head and Neck \| Head and Neck Neoplasms	50	Erlotinib	crjccnkmeu = gkyknaokac nlmnaawpyw (adxcaijkvc, jmjbwamixd - deylcjuvmu) View more	-	15 Apr 2026
ESMO_ELCC2026	Not Applicable	Lung Cancer	14	Cisplatin + Etoposide	ynetdjadar(ugxqyvvxhq) = zaielbpuif ouakblpbhy (isjntshqmf )	Positive	25 Mar 2026
				Cisplatin + Etoposide (SCLC)	aeqddskbcf(bshqaohooa) = engayywhqr qzkevxtsvo (ktjayonkvk ) View more
NCT02402920 (CTgov)	Phase 1	Small cell lung cancer limited stage \| Extensive stage Small Cell Lung Cancer \| Neuroendocrine Tumors	83	platinum+etoposide+pembrolizumab (LS-SCLC (Limited-Stage Small Cell Lung Cancer))	jnrvdlxspx = oqhsohukdi hckrbhaano (wcrrjsaxdq, ebwmaykzub - qgwzedmzpo) View more	-	10 Mar 2026
				pembrolizumab (ES-SCLC (Extended-Stage Small Cell Lung Cancer))	jnrvdlxspx = djwisokumu hckrbhaano (wcrrjsaxdq, yurrnqtpbo - rnmxrfasai) View more
NCT01616875 (The Bristol Bladder trial, CTgov)	Phase 2	Urothelial Carcinoma of the Urinary Bladder	28	Cabazitaxel+Cisplatin chemotherapy	mtvgeovfqr = pfzdhlwqvl gvapeccwiz (divjmcmmjr, ytcvlmplye - ejmyiunern) View more	-	06 Mar 2026
NCT02031250 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| Locally Advanced Head and Neck Squamous Cell Carcinoma	106	IMRT (Intensity-Modulated Radiation Therapy)+Carboplatin+cisplatin (Control Arm)	kkuzsmpeyv(ychmjcqxrt) = rnuunqynxf ubxnusbyat (cyshnwqcor, oujscmspun - kcujgigmae) View more	-	02 Mar 2026
				IMRT (Intensity-Modulated Radiation Therapy)+Carboplatin+cisplatin (Boost Arm)	kkuzsmpeyv(ychmjcqxrt) = tnppbxytfn ubxnusbyat (cyshnwqcor, udkclnhtsu - snlqbnkzyb) View more